Halozyme Therapeutics Inc (HALO)
53.76
+2.57
(+5.02%)
USD |
NASDAQ |
Jan 08, 16:00
53.71
-0.05
(-0.09%)
After-Hours: 20:00
Halozyme Therapeutics SG&A Expense (Quarterly): 41.24M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 75.11M |
| Lexicon Pharmaceuticals Inc | 39.59M |
| Novavax Inc | 70.75M |
| Kura Oncology Inc | 18.18M |
| TransMedics Group Inc | 42.66M |